Graymark Healthcare Promotes Dr. Steven Glen Hull to Chief Medical Officer

OKLAHOMA CITY, June 22, 2011 /PRNewswire/ -- Graymark Healthcare, Inc. (NASDAQ:GRMH), the nation's second largest provider of diagnostic sleep services and an innovator in comprehensive care for obstructive sleep apnea (OSA), has appointed Steven Glen Hull, MD as Graymark's new chief medical officer, effective immediately. Dr. Hull succeeds Kevin Lewis, MD, who departed Graymark to pursue other interests.

Dr. Hull brings to the position more than 15 years of sleep medicine experience, serving in a variety of upper-level management and director roles for numerous sleep centers and facilities. Dr. Hull was promoted to CMO from his position as president and medical director of somniTech and somniCare, divisions of Graymark that operate several sleep centers and sleep apnea therapy sites in the Midwest. He will maintain these positions as well as remain on staff in his part-time role as the director of sleep disorders and vaccine research for Vince and Associates Clinical Research, an independently owned research company. He also previously served as CEO of Avastra Sleep Centers, as well as associate medical director and sleep disorders clinical director with Kaiser Permanente Medical Group of Mid-America.

Dr. Hull's accomplished career also includes serving on the Blue Cross Blue Shield of Kansas City Medical Advisory Committee and as chairman of the Continuing Medical Education Committee for the American Academy of Sleep Medicine. He received his B.S. in Biology from the University of Illinois and earned his medical degree from Southern Illinois University, and was formerly a clinical assistant professor at the Department of Family Medicine, Kansas City University of Medicine and Biosciences. He is an accomplished researcher as a principal or sub-investigator in more than 275 clinical trials primarily focused on sleep. He is also a well-published author and former associate editor of the journal "Sleep" and "The Journal of Clinical Sleep Medicine."

"Steven brings to this important position a tremendous breadth of knowledge, experience and accomplishment in the sleep medicine field, as well as strong track record of effective leadership and sleep care at somniTech and somniCare," said Stanton Nelson, Graymark's chairman and CEO. "His passion for improving the quality of life of our patients supports our mission of providing comprehensive sleep management care. We look forward to his continued contributions to the field of sleep medicine as our new chief medical officer."

Dr. Hull commented: "This appointment is an honor as well as an exciting opportunity to advance the success and market expansion of Graymark's sleep care model.  Working closely with our medical directors and staff, I will focus on improving the outcomes of those we serve through our comprehensive sleep diagnostic services, treatment, and follow up programs."

Graymark operates a growing number of sleep laboratories nationwide, comprised of 24 standalone or IDTF facilities in large communities and 75 hospital or rural outreach locations. While the care environments may vary based on community need, Graymark ensures that the quality and comprehensiveness of the services provided remain consistently at the highest standard. To find out more or to locate a sleep center near you, visit www.graymarkhealthcare.com.

About Graymark Healthcare

Headquartered in Oklahoma City, Okla., Graymark Healthcare, Inc. (NASDAQ:GRMH) is the nation's second largest provider of sleep management solutions. In addition to diagnosing and treating over 80 sleep disorders, the company specializes in comprehensive care for Obstructive Sleep Apnea (OSA). Graymark offers its services through 99 sleep laboratories throughout the United States, including standalone or IDTF facilities, rural outreach sites and hospital or provider agreements. For more information, visit www.graymarkhealthcare.com.

Important Cautions Regarding Forward-Looking Statements

This press release may contain forward-looking statements that are based on the company's current expectations, forecasts and assumptions, including the expected closing date of the offering and the expected use of net proceeds of the offering. Forward-looking statements involve risks and uncertainties that could cause actual outcomes and results to differ materially from the company's expectations, forecasts and assumptions. These risks and uncertainties include risks and uncertainties not in the control of the company, including, without limitation, the current economic climate and other risks and uncertainties, including those enumerated and described in the company's filings with the Securities and Exchange Commission, which filings are available on the SEC's website at www.sec.gov. Unless otherwise required by law, the company disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

Company Contact:
Graymark Healthcare, Inc.
Stanton Nelson
Chairman and CEO
Tel 405-601-5300

Investor Relations:
Liolios Group, Inc.
Scott Liolios or Cody Slach
Tel 949-574-3860
[email protected]

SOURCE Graymark Healthcare, Inc.